By Giovanni Luca Ceresoli, MD Posted: June 24, 2020 Dr. Giovanni Luca Ceresoli Tumor-treating fields (TTFields) are a noninvasive, regional treatment based on the delivery of low-intensity alternating electric […] Read more
On the Backs of Specialists: LDCT Screening Has Heightened the Importance of Recent Improvements in Surgical and Radiation Techniques
Dr. Brendon StilesBy Brendon Stiles, MD, and Drew Moghanaki, MD, MPH Posted: June 24, 2020 Annual low-dose computed tomography (LDCT) detects more early-stage lung cancers and saves lives by preventing death in […] Read more
By Leah Lawrence Posted: June 24, 2020 In late February 2020, the U.S. Food and Drug Administration (FDA), American Association for Cancer Research (AACR), and the IASLC held its FDA/CDER-AACR-IASLC […] Read more
By Mariano Provencio, MD, PhD Posted: June 24, 2020 Data can help inform change to standard of care, but at what point do we say enough data is enough and […] Read more
By Leah Lawrence Posted: June 24, 2020 As part of its declaration on tobacco cessation after cancer diagnosis, the IASLC recommended that smoking status, both initially and during the study, […] Read more
TTFields in Mesothelioma (The STELLAR Trial): More Stars Needed in the Constellation
By Paul Baas, MD, PhD, and Cornedine J. de Gooijer, MD Posted: June 24, 2020 Recently, a manuscript by Ceresoli et al. was published in The Lancet Oncology.1 The study […] Read more
Lung Cancer in the Brazilian Health System: Screening, Drug Approvals, Barriers to Care, and Success Stories
By Ricardo Sales dos Santos, MD, PhD, and Juliana Franceschini, PhD Posted: June 24, 2020 Dr. Juliana Franceschini Dr. Ricardo Sales dos Santos […] Read more
By Kara Nyberg, PhD Posted: June 24, 2020 Given the variable response to immune checkpoint blockade, researchers have long sought to identify predictive biomarkers beyond PD-L1 to better select patients […] Read more
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
By Kara Nyberg, PhD Posted: June 24, 2020 An exploratory analysis of circulating free DNA (cfDNA) shows that lorlatinib confers potent antitumor activity in pretreated patients with ALK-positive NSCLC regardless […] Read more
Paul G. Kluetz, MD
Posted: June 24, 2020 Paul G. Kluetz, MD, has been named the FDA’s new Deputy Director of the OCE. During his 10 years with the FDA, Dr. Kluetz founded the […] Read more